567 related articles for article (PubMed ID: 23771985)
21. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients.
Haque T; Thomas JA; Falk KI; Parratt R; Hunt BJ; Yacoub M; Crawford DH
J Gen Virol; 1996 Jun; 77 ( Pt 6)():1169-72. PubMed ID: 8683203
[TBL] [Abstract][Full Text] [Related]
22. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.
Stevens SJ; Verschuuren EA; Pronk I; van Der Bij W; Harmsen MC; The TH; Meijer CJ; van Den Brule AJ; Middeldorp JM
Blood; 2001 Mar; 97(5):1165-71. PubMed ID: 11222357
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
24. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
[TBL] [Abstract][Full Text] [Related]
25. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients.
Levine SM; Angel L; Anzueto A; Susanto I; Peters JI; Sako EY; Bryan CL
Chest; 1999 Nov; 116(5):1273-7. PubMed ID: 10559086
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.
Barlev A; Zimmermann H; Guzman-Becerra N; Mehta A; Xing B; Macabeo B; Thivolet M; Brookhart MA
J Med Econ; 2024; 27(1):789-795. PubMed ID: 38727527
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
Haque T; Wilkie GM; Taylor C; Amlot PL; Murad P; Iley A; Dombagoda D; Britton KM; Swerdlow AJ; Crawford DH
Lancet; 2002 Aug; 360(9331):436-42. PubMed ID: 12241714
[TBL] [Abstract][Full Text] [Related]
28. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
Riddler SA; Breinig MC; McKnight JL
Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
[TBL] [Abstract][Full Text] [Related]
29. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R
Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
[TBL] [Abstract][Full Text] [Related]
30. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.
Verschuuren EA; Stevens SJ; van Imhoff GW; Middeldorp JM; de Boer C; Koëter G; The TH; van Der Bij W
Transplantation; 2002 Jan; 73(1):100-4. PubMed ID: 11792987
[TBL] [Abstract][Full Text] [Related]
31. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
[TBL] [Abstract][Full Text] [Related]
32. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients.
Hopwood PA; Brooks L; Parratt R; Hunt BJ; Bokhari M; Thomas JA; Yacoub M; Crawford DH
Transplantation; 2002 Jul; 74(2):194-202. PubMed ID: 12151731
[TBL] [Abstract][Full Text] [Related]
33. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease.
Green M; Cacciarelli TV; Mazariegos GV; Sigurdsson L; Qu L; Rowe DT; Reyes J
Transplantation; 1998 Dec; 66(12):1641-4. PubMed ID: 9884252
[TBL] [Abstract][Full Text] [Related]
34. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML
Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541
[TBL] [Abstract][Full Text] [Related]
36. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders.
Limaye AP; Huang ML; Atienza EE; Ferrenberg JM; Corey L
J Clin Microbiol; 1999 Apr; 37(4):1113-6. PubMed ID: 10074534
[TBL] [Abstract][Full Text] [Related]
37. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder.
Badley AD; Portela DF; Patel R; Kyle RA; Habermann TM; Strickler JG; Ilstrup DM; Wiesner RH; de Groen P; Walker RC; Paya CV
Liver Transpl Surg; 1996 Sep; 2(5):375-82. PubMed ID: 9346679
[TBL] [Abstract][Full Text] [Related]
38. Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation.
Gridelli B; Spada M; Riva S; Colledan M; Segalin A; Lucianetti A; Sonzogni A; Furione M; Baldanti F; Torre G
Transpl Int; 2000; 13 Suppl 1():S399-401. PubMed ID: 11112041
[TBL] [Abstract][Full Text] [Related]
39. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
Shapiro R; Nalesnik M; McCauley J; Fedorek S; Jordan ML; Scantlebury VP; Jain A; Vivas C; Ellis D; Lombardozzi-Lane S; Randhawa P; Johnston J; Hakala TR; Simmons RL; Fung JJ; Starzl TE
Transplantation; 1999 Dec; 68(12):1851-4. PubMed ID: 10628763
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr Virus Monitoring after an Allogeneic Hematopoietic Stem Cell Transplant: Review of the Recent Data and Current Practices in Canada.
Ratiu C; Dufresne SF; Thiant S; Roy J
Curr Oncol; 2024 May; 31(5):2780-2795. PubMed ID: 38785492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]